12.51
-1.26%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Tiantan Biological Products Corp
Its shares trade on Shanghai under the ticker 600161.SS. It has been listed since 16 June 1998. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.14bn and net income of CN¥1.09bn. At that date it held total assets of CN¥16.64bn and shareholders' equity of CN¥11.74bn.
Beijing Tiantan Biological Products Corp. Ltd. engages in the research and development, production and sale of biological products. The company is headquartered in Beijing, Beijing. The Company’s primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The firm mainly distributes its products within domestic markets and to Hong Kong markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 1998
- Employees
- 4,568
- Website
- tiantanbio.com ↗
Leadership
Pay as last reported
- Mr. Huichuan YangChairman of the Board, Acting Secretary of the Board, since 2011CN¥739,800
- Mr. Hongqing WangChief Financial OfficerCN¥39,200
- Ms. Xiang CiChief Compliance Officer, General CounselCN¥1.7m
- Mr. Yanlin HeDeputy General Manager, Director, since 2018CN¥1.9m
- Mr. Ding YuDeputy General Manager
- Ms. Yana LiuDirector, since 2021CN¥2.3m
- Mr. Jinglin SunDirector
- Ms. Yan FangIndependent DirectorCN¥240,000
- Ms. Fenling GuIndependent DirectorCN¥240,000
- Mr. Mu ZhangIndependent DirectorCN¥140,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 67
- Social
- 45
- Governance
- 33
- Direct emissions (scope 1)
- 10,542.49 t
- Energy emissions (scope 2)
- 97,930.43 t
- Women in the workforce
- 57.49339%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Tiantan Biological Products Corp Ltd employs 4,568 full-time employees for R&D and production.
- The company produces key vaccines including H1N1, hepatitis B, and MMR for domestic and Hong Kong markets.
- Beijing Tiantan's product portfolio includes HSA and IVIG, critical for blood product applications.
Weaknesses
- The company's primary market is limited to domestic and Hong Kong, restricting global reach.
- Beijing Tiantan's reliance on biological products may expose it to regulatory changes in China.
- The firm's business is concentrated in the Health Care sector without diversification into other industries.
Opportunities
- Expanding into international markets could leverage Beijing Tiantan's vaccine expertise.
- Growing demand for HSA and IVIG in China presents new revenue streams.
- Increasing focus on biotechnology in China offers potential for R&D partnerships.
Threats
- Regulatory changes in China could impact the production and sale of biological products.
- Competition from domestic biotech firms may challenge Beijing Tiantan's market position.
- Economic downturns in China might reduce public health spending on vaccines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.